Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trialAnna Maria Di Giacomo, Michele Maio, Michele Guida et al.|European Journal of Cancer|2024Cited by 39
1084MO Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trialAnna Maria Di Giacomo, Michele Maio, Michele Del Vecchio et al.|Annals of Oncology|2023Cited by 2